The emerging roles of forkhead box (Fox) proteins in cancer

By S. Myatt, E. Lam. Nature Reviews. Cancer, 2007

1,088 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/b00e253eac1a21ad12c689ffb0bd84c8460c0b84

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Cdks, cyclins and CKIs: roles beyond cell cycle regulation (2013, background): “FoxM1 is a member of the forkhead box (Fox) superfamily of transcription factors (Hannenhalli and Kaestner, 2009; Myatt and Lam, 2007), target genes of which include essential regulators of mitosis and components of the spindle assembly checkpoint (Laoukili et al.”
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity (2011, neutral): “Because inhibition of the PI3K-AKT pathway causes dephosphorylation of FOXO proteins and prevents their nuclear translocation , we investigated whether mammalian FOXO transcription factors may be involved in the induction of the RTKs by the AKT inhibitor (Myatt and Lam, 2007).”
Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2 (2016, background): “Deregulation of Foxo3 is associated with cancer development (11), which appears to be the consequence of increased Akt activity or Phosphatase and tensin homolog (PTEN) inactivation and Foxo3 is thus classified as a tumor suppressor gene (11,12).”
Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity (2016, background): “Downregulation of Foxo3 is often observed in cancer development.(14,15) Both circ-Foxo3 and Foxo3 mRNA are encoded by the FOXO3 gene.”
Integrated Genomic Analyses of Ovarian Carcinoma (2011, background): “Absher(44), Lindsay Waite(44), Gavin Sherlock(79), James D.”
CircRNA: a novel type of biomarker for cancer (2017, background): “Foxo3 acts as a tumor suppressor and correlates with cancer progression [60].”